Comparing docetaxel with gemcitabine as second-line chemotherapy in patients with advanced non-small cell lung cancer: A single institute randomized phase II study
Journal Title: Journal of Cancer Research & Therapy - Year 2015, Vol 3, Issue 1
Abstract
Background: Platinum-based doublet chemotherapy is the backbone of treatment in advanced non-small cell lung cancer (NSCLC) however second-line treatment options are controversial particularly in patients with borderline performance status (PS) of 2. The aim of this study was to compare efficacy and toxicity of weekly docetaxel versus gemcitabine in this clinical setting. Patients and methods: A total of 70 patients with advanced (stage IIIB, IV) NSCLC entered this single institute study. Cases of this study had experienced disease progression after the first-line platinum-based doublet chemotherapy, with PS 0- 2 in “Eastern Cooperative Oncology Group” scale. They were randomly assigned by stratified blocks to receive docetaxel 35 mg/m2 (Arm A, n=34) or gemcitabine 1000 mg/m2 (Arm B, n=36) days 1, 8 and 15, every three weeks, for up to six cycles. Primary end point was progression free survival (PFS) and secondary end points were objective response rate, disease control rate, median overall survival (OS) and toxicity. Dose modification was permitted upon clinician’s discretion for each individual patient. Results: Median of PFS was 2.02 months in arm A and 2.63 months in arm B (HR= 1.279; 95% CI: 0.710-2.304, P= 0.551). Although median OS for arm A was numerically greater (9.2 months) than arm B (8.3 months) it was statistically non-significant (HR= 1.384; 95% CI: 0.632 to 2.809, P= 0.59). Objective response was higher in Arm B than that in Arm A (P= 0.20) but disease control rates were statistically different in both arms (P= 0.034). Statistically significant differences in term of leukopenia was seen in arm B (P= 0.013). Conclusion: This study, with limited number of cases, indicates that in advanced NSCLC, weekly docetaxel and gemcitabine are reasonable second-line treatment options with statistically similar effectiveness in terms of PFS and median OS with manageable toxicities in patients with PS 0-2.
Authors and Affiliations
Khosravi A, Esfahani-Monfared Z, Karimi SH, Emami H, Khodadad K
Keywords
Related Articles
- EP ID EP544835
- DOI 10.14312/2052-4994.2015-1
- Views 46
- Downloads 0
Improving patient data quality by integrating oncology practice and state cancer registry tumor staging information: Feasibility and future value
Background: The transition in oncology to electronic charting offers the potential to improve the quality of patient care and value of observational research. Data fields that are more complete, have common standards, an...
Antitumor activity of Papua’s Myrmecodia pendans in human oral tongue squamous cell carcinoma cell line through induction of cyclin-dependent kinase inhibitor p27Kip1 and suppression of cyclin E
Oral tongue squamous cell carcinoma (OTSCC) is one of the most common cancers encountered in Indonesia, due to the prevalent habits of tobacco chewing, alcohol drinking and smoking. Oral tongue cancer is characterized by...
Stem cells’ guided gene therapy of cancer: New frontier in personalized and targeted therapy
Diagnosis and therapy of cancer remain to be the greatest challenges for all physicians working in clinical oncology and molecular medicine. The grim statistics speak for themselves with reports of 1,638,910 men and wome...
Usefulness of the Glasgow prognostic score for predicting survival in patients with resected non-small cell lung cancer
Background: Few studies have investigated whether the Glasgow prognostic score (GPS), an inflammation based prognostic score, is useful for postoperative prognosis of non-small cell lung cancer (NSCLC). Materials and met...
The positive sentinel lymph node biopsy- can we predict which patients will benefit from further surgery?
Introduction: Although sentinel lymph node biopsy (SLNB) is the gold standard for clinical and radiological negative axillae in breast cancer, the subsequent management of positive nodes is currently under scrutiny with...